S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
NYSE:QGEN

QIAGEN Stock Competitors

$53.44
-1.50 (-2.73 %)
(As of 10/27/2021 04:00 PM ET)
Add
Compare
Today's Range
$53.42
$55.09
50-Day Range
$50.62
$56.83
52-Week Range
$45.33
$59.00
Volume
668,273 shs
Average Volume
763,685 shs
Market Capitalization
$12.18 billion
P/E Ratio
25.94
Dividend Yield
N/A
Beta
0.21

QIAGEN (NYSE:QGEN) Vs. BIIB, SGEN, TECH, RGEN, ARGX, XLRN, NVAX, NBIX, CRSP, and EXEL

Should you be buying QIAGEN stock or one of its competitors? The main competitors of QIAGEN include Biogen (BIIB), Seagen (SGEN), Bio-Techne (TECH), Repligen (RGEN), argenx (ARGX), Acceleron Pharma (XLRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), and Exelixis (EXEL). These companies are all part of the "biological products, except diagnostic" industry.

QIAGEN vs.

Seagen (NASDAQ:SGEN) and QIAGEN (NYSE:QGEN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, QIAGEN had 7 more articles in the media than Seagen. MarketBeat recorded 13 mentions for QIAGEN and 6 mentions for Seagen. Seagen's average media sentiment score of 0.32 beat QIAGEN's score of 0.20 indicating that Seagen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seagen
0 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
QIAGEN
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

88.2% of Seagen shares are owned by institutional investors. Comparatively, 52.2% of QIAGEN shares are owned by institutional investors. 27.6% of Seagen shares are owned by insiders. Comparatively, 9.0% of QIAGEN shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Seagen has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Seagen has a net margin of 25.06% compared to QIAGEN's net margin of 21.92%. QIAGEN's return on equity of 21.31% beat Seagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Seagen 25.06% 19.02% 16.03%
QIAGEN 21.92% 21.31% 10.34%

Seagen received 479 more outperform votes than QIAGEN when rated by MarketBeat users. Likewise, 67.04% of users gave Seagen an outperform vote while only 62.26% of users gave QIAGEN an outperform vote.

CompanyUnderperformOutperform
SeagenOutperform Votes
710
67.04%
Underperform Votes
349
32.96%
QIAGENOutperform Votes
231
62.26%
Underperform Votes
140
37.74%

Seagen presently has a consensus price target of $179.56, indicating a potential upside of 2.83%. QIAGEN has a consensus price target of $52.27, indicating a potential downside of 2.20%. Given Seagen's higher possible upside, equities analysts plainly believe Seagen is more favorable than QIAGEN.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seagen
0 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.55
QIAGEN
0 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.58

Seagen has higher revenue and earnings than QIAGEN. QIAGEN is trading at a lower price-to-earnings ratio than Seagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$2.18 billion14.60$613.67 million$3.3052.91
QIAGEN$1.87 billion6.51$359.19 million$2.1524.86

Summary

Seagen beats QIAGEN on 14 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QIAGEN (NYSE:QGEN) vs. Its Competitors

TypeQIAGENBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$12.18B$3.97B$5.08B$15.73B
Dividend YieldN/A2.15%1.96%2.78%
P/E Ratio25.9417.0332.4926.81
Price / Sales6.513,318.143,180.0332.12
Price / Cash16.85110.1542.2125.73
Price / Book4.366.8911.3013.80
Net Income$359.19M$2.61M$90.71M$356.50M
7 Day PerformanceN/A-5.15%-4.34%-0.74%
1 Month Performance3.73%-7.30%-4.29%1.54%
1 Year Performance9.76%37.44%45.80%62.46%

QIAGEN Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIIB
Biogen
2.5514 of 5 stars
$259.95
-4.3%
$378.28
-45.5%
N/A$38.18B$13.44B20.869,100Analyst Report
Analyst Revision
SGEN
Seagen
2.1193 of 5 stars
$174.61
-1.8%
$178.44
-2.2%
N/A$31.77B$2.18B53.562,092Analyst Report
TECH
Bio-Techne
2.2142 of 5 stars
$509.77
-1.8%
$458.00
-10.2%
N/A$19.92B$931.03M146.912,300Upcoming Earnings
Analyst Upgrade
RGEN
Repligen
2.3831 of 5 stars
$271.04
-1.0%
$306.14
-13.0%
N/A$14.88B$366.26M151.421,128
ARGX
argenx
1.9356 of 5 stars
$279.58
-0.8%
$351.69
-25.8%
N/A$14.38B$41.60M-40.00336Short Interest ↓
XLRN
Acceleron Pharma
2.04 of 5 stars
$173.80
-0.0%
$171.29
-1.4%
N/A$10.58B$92.52M-46.85312Upcoming Earnings
NVAX
Novavax
2.125 of 5 stars
$141.55
-4.6%
$249.60
-76.3%
N/A$10.54B$475.60M-10.32791Upcoming Earnings
Gap Up
NBIX
Neurocrine Biosciences
2.6533 of 5 stars
$101.26
-0.6%
$119.46
-18.0%
N/A$9.57B$1.05B27.22845Upcoming Earnings
CRSP
CRISPR Therapeutics
2.4228 of 5 stars
$92.78
-2.5%
$162.20
-74.8%
N/A$7.07B$720,000.0018.16410Short Interest ↑
EXEL
Exelixis
2.7481 of 5 stars
$21.30
-1.7%
$34.00
-59.6%
N/A$6.71B$987.54M73.45773Upcoming Earnings
Analyst Upgrade
BEAM
Beam Therapeutics
2.1248 of 5 stars
$91.79
-3.0%
$119.50
-30.2%
N/A$6.09B$20,000.00-13.19181
TWST
Twist Bioscience
1.7381 of 5 stars
$114.25
-3.0%
$118.00
-3.3%
N/A$5.79B$90.10M-39.95525Analyst Upgrade
Insider Selling
KOD
Kodiak Sciences
2.1562 of 5 stars
$111.90
-0.2%
$131.09
-17.2%
N/A$5.76BN/A-29.2272
DNLI
Denali Therapeutics
2.2464 of 5 stars
$46.88
-1.7%
$86.00
-83.4%
N/A$5.70B$335.66M161.66291Upcoming Earnings
HALO
Halozyme Therapeutics
2.6188 of 5 stars
$37.42
-2.8%
$54.14
-44.7%
N/A$5.33B$267.59M23.99136Upcoming Earnings
VIR
Vir Biotechnology
1.9132 of 5 stars
$39.15
-2.9%
$68.17
-74.1%
N/A$5.25B$76.37M-16.59327Upcoming Earnings
Analyst Upgrade
FATE
Fate Therapeutics
2.3264 of 5 stars
$54.84
-8.2%
$111.00
-102.4%
N/A$5.22B$31.43M-23.34279Upcoming Earnings
Insider Selling
ABCM
Abcam
1.199 of 5 stars
$22.84
-0.3%
$22.00
-3.7%
N/A$5.18B$401.06M126.891,500
ADPT
Adaptive Biotechnologies
2.1448 of 5 stars
$32.36
-4.5%
$60.25
-86.2%
N/A$4.56B$98.38M-26.10622Upcoming Earnings
IOVA
Iovance Biotherapeutics
1.6833 of 5 stars
$25.48
-2.9%
$39.00
-53.1%
N/A$3.95BN/A-13.34241Upcoming Earnings
SANA
Sana Biotechnology
1.5699 of 5 stars
$20.50
-3.3%
$38.50
-87.8%
N/A$3.85BN/A-1.77265Upcoming Earnings
ADGI
Adagio Therapeutics
1.675 of 5 stars
$31.79
-3.1%
$47.50
-49.4%
N/A$3.54BN/A0.002,021
SWTX
SpringWorks Therapeutics
2.5198 of 5 stars
$67.27
-6.9%
$117.50
-74.7%
N/A$3.30B$35M-36.1778Analyst Downgrade
High Trading Volume
RXRX
Recursion Pharmaceuticals
1.6714 of 5 stars
$18.85
-1.5%
$33.33
-76.8%
N/A$3.18B$3.96M0.00218
DNA
Ginkgo Bioworks
1.5917 of 5 stars
$14.33
-1.0%
$14.50
-1.2%
N/A$3.09BN/A0.00N/A
SRNG
Soaring Eagle Acquisition
0.1667 of 5 stars
$14.33
-1.0%
N/AN/A$3.09BN/A0.00N/A
KYMR
Kymera Therapeutics
2.1498 of 5 stars
$56.61
-0.2%
$76.43
-35.0%
N/A$2.89B$34.03M-37.2475Upcoming Earnings
RLAY
Relay Therapeutics
2.325 of 5 stars
$30.25
-2.9%
$51.25
-69.4%
N/A$2.80B$82.65M0.002,020Short Interest ↑
BCRX
BioCryst Pharmaceuticals
2.2375 of 5 stars
$14.93
-3.0%
$20.80
-39.3%
N/A$2.67B$17.81M-12.44246Upcoming Earnings
EDIT
Editas Medicine
2.1351 of 5 stars
$36.80
-3.0%
$54.88
-49.1%
N/A$2.51B$90.73M-14.43235Short Interest ↑
TIL
Instil Bio
1.7831 of 5 stars
$19.03
-0.9%
$30.40
-59.7%
N/A$2.45B$140,000.000.00150
VCEL
Vericel
2.0381 of 5 stars
$50.58
-0.5%
$53.00
-4.8%
N/A$2.36B$124.18M281.02273
ALLO
Allogene Therapeutics
2.4277 of 5 stars
$15.94
-0.5%
$36.23
-127.3%
N/A$2.27BN/A-8.71265Upcoming Earnings
Short Interest ↓
VALN
Valneva
1.4015 of 5 stars
$47.37
-11.2%
$36.00
-24.0%
N/A$2.25B$126.02M0.00500Short Interest ↑
Lockup Expiration
Gap Down
CCCC
C4 Therapeutics
2.0379 of 5 stars
$45.05
-0.3%
$45.17
-0.3%
N/A$2.18B$33.19M-7.7399
NSTG
NanoString Technologies
1.7481 of 5 stars
$47.89
-0.1%
$72.00
-50.3%
N/A$2.18B$117.32M-20.73579
RVMD
Revolution Medicines
2.5998 of 5 stars
$27.59
-1.7%
$34.67
-25.6%
N/A$2.03B$42.98M-13.33125
SRNE
Sorrento Therapeutics
1.9917 of 5 stars
$6.69
-0.6%
$29.00
-333.5%
N/A$2.03B$39.99M-5.77502News Coverage
OCGN
Ocugen
1.5181 of 5 stars
$9.61
-4.8%
$7.66
-20.3%
N/A$1.91B$42.62M-31.0015Insider Selling
ALEC
Alector
2.2464 of 5 stars
$21.61
-8.3%
$39.00
-80.5%
N/A$1.75B$21.10M-8.06171News Coverage
IMCR
Immunocore
1.3415 of 5 stars
$37.93
-0.2%
$54.75
-44.3%
N/A$1.64B$38.67M-10.592,020Short Interest ↓
ALVR
AlloVir
2.3264 of 5 stars
$24.28
-1.4%
$48.33
-99.1%
N/A$1.58B$170,000.00-9.3753Analyst Upgrade
Insider Selling
RGNX
REGENXBIO
2.4873 of 5 stars
$35.22
-2.2%
$58.75
-66.8%
N/A$1.50B$154.57M-9.87306Upcoming Earnings
Analyst Report
BLUE
bluebird bio
2.2553 of 5 stars
$22.06
-5.0%
$37.44
-69.7%
N/A$1.49B$250.73M-1.751,213Upcoming Earnings
INBX
Inhibrx
1.9781 of 5 stars
$38.64
-1.3%
$45.00
-16.5%
N/A$1.46B$12.89M-16.8088
CRBU
Caribou Biosciences
1.6665 of 5 stars
$22.79
-1.6%
$29.67
-30.2%
N/A$1.37BN/A0.002,021Short Interest ↓
REPL
Replimune Group
2.3865 of 5 stars
$28.55
-1.6%
$58.60
-105.3%
N/A$1.34BN/A-15.52152Upcoming Earnings
Analyst Upgrade
RUBY
Rubius Therapeutics
2.1265 of 5 stars
$14.40
-6.7%
$28.33
-96.8%
N/A$1.29BN/A-6.92204
ATRA
Atara Biotherapeutics
1.8121 of 5 stars
$14.98
-1.5%
$30.33
-102.5%
N/A$1.27BN/A-4.12437Analyst Upgrade
OMGA
Omega Therapeutics
1.3548 of 5 stars
$26.34
-0.3%
$29.50
-12.0%
N/A$1.26BN/A0.002,021Analyst Upgrade
This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.